00:00 Longeviron, a clinical stage biotechnology company developing cellular therapies for
00:06 life-threatening and chronic aging-related conditions such as hypoplastic left heart
00:10 syndrome, Alzheimer's disease, and aging-related frailty, announced today that its registration
00:14 statement previously filed with the Securities and Exchange Commission to conduct a tradable
00:18 subscription rights offering has been declared effective and that it's finalized the rights
00:22 offering calendar.
00:23 The rights offering is being made through a distribution of five tradable subscription
00:27 rights to be listed on the NASDAQ capital market under the ticker symbol LGVNR to purchase
00:32 shares of Class A common stock for each share of common stock and warrant to purchase common
00:36 stock owned on the record date at a $3 subscription price per share.
00:40 The registration statement also covers the placement of unsubscribed shares of Class
00:43 A common stock for an additional period of up to 45 days following expiration of the
00:48 offering as well as the potential resale of subscription rights by the company's principal
00:52 stockholders, directors, and executive officers during the period for which the subscription
00:56 rights may be transferred in accordance with the terms of the rights offering.
00:59 (upbeat music)
Comments